News | Antiplatelet and Anticoagulation Therapies | May 18, 2018

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin

Understanding the real-world performance of systemic anticoagulation in atrial fibrillation

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral anticoagulants do not maintain adherence above 80 percent. This leads to increased risks for thromboembolic events. This was according to a new study presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

Anticoagulation (AC) mitigates risk of thromboembolic events (TE) in patients with non-valvular atrial fibrillation (AF or Afib). Warfarin for decades, and recently direct oral anticoagulants (DOACs — a newer term for novel oral anticoagulants, or NOAC) have been effective. Real-world data have pointed to inconsistent adherence to anticoagulation, but it is not clear if event risk is elevated during gaps or if events occur even during periods of adherence.

The cohort included 52,365 patients prescribed warfarin and 67,686 prescribed any of the four DOACs. Lower adherence occurred in 47% of patients using warfarin and 31% on DOACs. Compared to higher-adherence warfarin, thromboembolic events were 14% less likely for higher-adherence DOAC (P<0.001), 48% more likely for lower-adherence warfarin (P<0.001) and 69% more likely for lower-adherence DOAC (P<0.001).

This observational cohort study evaluated administrative claims for patients in the IBM Watson Health Market Scan databases receiving a prescription of warfarin or a DOAC for anticoagulation for nonvalvular atrial fibrillation (NVAF) from  2015 to 2016. Exclusions were CHA2 DS2-VASc 0-1, transient AF, other requirement for AC, thrombocytopenia and anemia. The remaining patients were stratified based on index prescription (warfarin or DOAC). Outcomes, through December 2016, were hospitalization for TE (ischemic stroke or systemic embolism), hemorrhagic stroke or major bleeding. Event rates are reported for warfarin and DOACs at higher adherence (dosage covering >80% of days) and lower adherence (covering 40-80% of days). A Cox proportional-hazards model will incorporate basic characteristics, comorbidities and a time-dependent covariate for anticoagulation based on prescription dosage to associate adherence to outcomes.

Researchers said they plan to update the abstract with 2017 data and use the time-dependent Cox model to determine if event risk is higher during medication usage or gaps in adherence. Patients with lower adherence may be candidates for device therapies that obviate the need for chronic AC.

The study was presented by Dhanunjaya R. Lakkireddy, M.D., FHRS, from Kansas City Heart Rhythm Institute in Overland Park, Kansas.

 

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

#HRS2018 #HRS18

Related Content

Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018
Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional bleeding, a new...
Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Overlay Init